Why the study?
Ticagrelor is practically insoluble in water with an absolute bioavailability of about 36 percent, prompting efforts to improve its water solubility and bioavailability.
This study describes the formulation of a ticagrelor oral liquid self nano-emulsion aimed at improving the drug's water solubility and bioavailability.
Answers are grounded in this paper and cite their sources.
SNEDDS formulation improved ticagrelor release and exposure in animals; leaves open human translation and clinical adoption.
Ticagrelor is a new drug use to inhibit platelet aggregation induced by adenosine di phosphate (ADP) that's used to reduce atherothrombotic occurring in adults with acute coronary syndrome. Ticagrelor is class IV drug according to BCS drug classification, which is practically insoluble in water 10 g/ml, with an absolute bioavailability of about 36 %, so this study intended to improve its water solubility and bioavailability.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: